Last reviewed · How we verify

NCT04972903

Impact of Malnutrition on Pharmacokinetic of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children (TB-Speed TB-PK)

Completed Last updated 25 February 2025
What this trial tests

trial in Tuberculosis in 85 participants. Completed in 22 March 2023.

Timeline
8 November 2021
Primary endpoint
22 March 2022
22 March 2023

Quick facts

Lead sponsorInstitut National de la Santé Et de la Recherche Médicale, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment85
Start date8 November 2021
Primary completion22 March 2022
Estimated completion22 March 2023
Sites4 locations across Zambia, Uganda

Conditions studied

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

Adults 6 Months to 5, any sex, with Tuberculosis or Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children in Uganda and Zambia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing